TandemAI and Perpetual Medicines Announce Strategic Merger to Expand Physics and AI-Based Drug Discovery Capabilities
Summary
TandemAI and Perpetual Medicines have merged to form a combined drug discovery company under the TandemAI name. The new company will expand its AI, physics-based modeling, wet-lab, and peptide discovery capabilities. TandemAI says it already works with more than 150 partners and expects more client programs to move into clinical trials soon. The merger strengthens its position in AI-driven life sciences research and broadens its ability to support pharma partners across small molecules and peptides.
Classifications
industries
No industries detected
applications
AI & Machine learning
AskAI Classifications
Labels
SaaS
Bioinformatics Software
Drug Discovery Software
Linked Companies
TandemAI
$10M to $25M